tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Health Catalyst price target lowered to $6.50 from $7 at Citi

Citi lowered the firm’s price target on Health Catalyst (HCAT) to $6.50 from $7 and keeps a Buy rating on the shares. The firm expects another volatile earnings season for its health tech coverage. Health tech companies should be well-insulated from tariffs and a potential recession, which would lead to less earnings volatility this year versus the broader market, however, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1